We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.75B
1-Year Est. Return 68.58%
This Fund
S&P 500
This Quarter Est. Return
+1.11%
1 Year Est. Return
+68.58%
3 Year Est. Return
+159.39%
5 Year Est. Return
+187.79%
10 Year Est. Return
+1,025.09%
AUM
$4.2B
AUM Growth
-$1.07B
Cap. Flow
-$834M
Cap. Flow %
-19.85%
Top 10 Hldgs %
41.95%
Holding
195
New
19
Increased
34
Reduced
87
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$203M
2
GILD icon
Gilead Sciences
GILD
+$156M
3
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$146M
4
AMGN icon
Amgen
AMGN
+$98.7M
5
VRDN icon
Viridian Therapeutics
VRDN
+$70.3M

Top Sells

Rank Stock Value
1
RVMD icon
Revolution Medicines
RVMD
+$350M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$235M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$225M
4
RNAM
Avidity Biosciences
RNAM
+$190M
5
FOLD
Amicus Therapeutics
FOLD
+$153M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
2 Energy 0.07%
3 Technology 0.06%
4 Financials 0.03%
5 Consumer Discretionary 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COO icon
51
Cooper Companies
COO
$14.9B
$19.5M 0.46%
272,184
-19,775
-7% -$1.56M
MCK icon
52
McKesson
MCK
$101B
$19.3M 0.46%
22,352
-2,746
-11% -$2.45M
BDX icon
53
Becton Dickinson
BDX
$49.9B
$19.2M 0.46%
121,887
-143,775
-54% -$26.4M
HCA icon
54
HCA Healthcare
HCA
$87.8B
$17.9M 0.43%
37,765
-6,141
-14% -$3.09M
GKOS icon
55
Glaukos
GKOS
$11B
$15.7M 0.37%
145,703
-116,232
-44% -$13.1M
ELV icon
56
Elevance Health
ELV
$87.1B
$15.4M 0.37%
52,518
-17,127
-25% -$5.63M
ZBH icon
57
Zimmer Biomet
ZBH
$19.1B
$14.1M 0.33%
155,571
-83,109
-35% -$7.63M
PRCT icon
58
Procept Biorobotics
PRCT
$1.24B
$12.6M 0.3%
502,286
-13,144
-3% -$370K
LIVN icon
59
LivaNova
LIVN
$4.5B
$11.8M 0.28%
+186,185
New +$12M
HUM icon
60
Humana
HUM
$46.5B
$11.2M 0.27%
64,498
-8,583
-12% -$1.76M
TMDX icon
61
Transmedics
TMDX
$3.05B
$10.1M 0.24%
101,139
+3,254
+3% +$424K
VEEV icon
62
Veeva Systems
VEEV
$40B
$9.93M 0.24%
56,517
-24,012
-30% -$4.72M
CNC icon
63
Centene
CNC
$33.2B
$8.55M 0.2%
261,066
-12,608
-5% -$517K
TEVA icon
64
Teva Pharmaceuticals
TEVA
$42.6B
$7.53M 0.18%
250,082
-77,781
-24% -$2.5M
THC icon
65
Tenet Healthcare
THC
$21.5B
$7.22M 0.17%
38,269
-1,970
-5% -$415K
TXG icon
66
10x Genomics
TXG
$7.38B
$7M 0.17%
329,492
+7,432
+2% +$149K
CVS icon
67
CVS Health
CVS
$124B
$6.42M 0.15%
89,363
-19,695
-18% -$1.52M
NTRA icon
68
Natera
NTRA
$44.7B
$6.34M 0.15%
31,694
-24,342
-43% -$5.24M
WAY
69
Waystar Holding Corp
WAY
$4.75B
$6.18M 0.15%
256,139
+14,405
+6% +$382K
MDLN
70
Medline Inc
MDLN
$31.2B
$6.08M 0.14%
136,635
+18,915
+16% +$835K
INSP icon
71
Inspire Medical Systems
INSP
$1.67B
$5.14M 0.12%
99,735
-1,026
-1% -$71.8K
PRVA icon
72
Privia Health
PRVA
$2.81B
$4.66M 0.11%
226,703
-221,460
-49% -$4.99M
PEN icon
73
Penumbra
PEN
$12.9B
$4.03M 0.1%
12,267
-123,128
-91% -$41.7M
RNA
74
Atrium Therapeutics
RNA
$217M
$3.52M 0.08%
+263,096
New +$3.7M
PFE icon
75
Pfizer
PFE
$153B
$3.02M 0.07%
107,635
+50,788
+89% +$1.35M
1 2
3
4 5

Similar funds

SAMU
SONA Asset Management (US) New York $4.74B AUM 11.18% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
AA
Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return
DCP
Darsana Capital Partners New York $4.7B AUM 50.56% 1-Year Est. Return
EI
EFG International Zurich $4.67B AUM
MA
Mutual Advisors Omaha, Nebraska $4.67B AUM 17.48% 1-Year Est. Return
BMO
Beck Mack & Oliver New York $4.85B AUM 9.66% 1-Year Est. Return

Bellevue Group's Q1 2026 Portfolio in Review

As of Q1 2026, Bellevue Group held 195 positions worth $4.2B, down 20% from $5.28B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group withdrew a net $834M in Q1 2026, closing 40 positions and reducing 87 holdings. Its most notable exit was Avidity Biosciences, an estimated $190M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Energy and Technology.

Against the trend, Bellevue Group opened a new position in Vaxcyte worth $69.2M.

  • Bellevue Group's largest Q1 2026 buy was Vaxcyte: 1,190,697 shares worth $69.2M.
  • Bellevue Group added most to Regeneron Pharmaceuticals in Q1 2026, an estimated $203M increase.
  • Bellevue Group's biggest Q1 2026 reduction was Revolution Medicines, cutting an estimated $350M.
  • Bellevue Group fully exited Avidity Biosciences in Q1 2026, selling an estimated $190M.
  • Bellevue Group's ten largest holdings make up 42% of its $4.2B portfolio in Q1 2026.
  • Bellevue Group opened 19 new positions and closed 40 in Q1 2026.
  • Bellevue Group's portfolio value fell 20% quarter-over-quarter to $4.2B.

Based on Bellevue Group's 13F filing for Q1 2026, filed 15 May 2026.